EyePoint EYPT Stock
EyePoint Price Chart
EyePoint EYPT Financial and Trading Overview
| EyePoint stock price | 14.38 USD |
| Previous Close | 13.58 USD |
| Open | 13.62 USD |
| Bid | 9.88 USD x 200 |
| Ask | 17.43 USD x 200 |
| Day's Range | 13.49 - 14.01 USD |
| 52 Week Range | 7.94 - 19.11 USD |
| Volume | 821.15K USD |
| Avg. Volume | 959.03K USD |
| Market Cap | 1.15B USD |
| Beta (5Y Monthly) | 1.748 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.51 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37 USD |
EYPT Valuation Measures
| Enterprise Value | 1.28B USD |
| Trailing P/E | N/A |
| Forward P/E | -4.864878 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 151.18742 |
| Price/Book (mrq) | 34.671715 |
| Enterprise Value/Revenue | 167.578 |
| Enterprise Value/EBITDA | -4.567 |
Trading Information
EyePoint Stock Price History
| Beta (5Y Monthly) | 1.748 |
| 52-Week Change | 64.00% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 19.11 USD |
| 52 Week Low | 7.94 USD |
| 50-Day Moving Average | 13.28 USD |
| 200-Day Moving Average | 14.1 USD |
EYPT Share Statistics
| Avg. Volume (3 month) | 959.03K USD |
| Avg. Daily Volume (10-Days) | 1.21M USD |
| Shares Outstanding | 83.84M |
| Float | 70.47M |
| Short Ratio | 16.43 |
| % Held by Insiders | 3.67% |
| % Held by Institutions | 111.82% |
| Shares Short | 15.1M |
| Short % of Float | 18.98% |
| Short % of Shares Outstanding | 18.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2018 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -450.65% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -54.13% |
| Return on Equity (ttm) | -102.70% |
Income Statement
| Revenue (ttm) | 7.61M USD |
| Revenue Per Share (ttm) | 0.1 USD |
| Quarterly Revenue Growth (yoy) | 161.69% |
| Gross Profit (ttm) | -224748992 USD |
| EBITDA | -279375008 USD |
| Net Income Avi to Common (ttm) | -271599008 USD |
| Diluted EPS (ttm) | -3.51 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 45.26M USD |
| Total Cash Per Share (mrq) | 0.48 USD |
| Total Debt (mrq) | 17.62M USD |
| Total Debt/Equity (mrq) | 46.82 USD |
| Current Ratio (mrq) | 6.661 |
| Book Value Per Share (mrq) | 0.396 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -267539008 USD |
| Levered Free Cash Flow (ttm) | -168724992 USD |
Profile of EyePoint
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 480 Pleasant Street |
| ZIP | 02472 |
| Phone | 617 926 5000 |
| Website | https://eyepoint.bio |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 214 |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Q&A For EyePoint Stock
What is a current EYPT stock price?
EyePoint EYPT stock price today per share is 14.38 USD.
How to purchase EyePoint stock?
You can buy EYPT shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for EyePoint?
The stock symbol or ticker of EyePoint is EYPT.
Which industry does the EyePoint company belong to?
The EyePoint industry is Biotechnology.
How many shares does EyePoint have in circulation?
The max supply of EyePoint shares is 83.84M.
What is EyePoint Price to Earnings Ratio (PE Ratio)?
EyePoint PE Ratio is now.
What was EyePoint earnings per share over the trailing 12 months (TTM)?
EyePoint EPS is -3.51 USD over the trailing 12 months.
Which sector does the EyePoint company belong to?
The EyePoint sector is Healthcare.
EyePoint EYPT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}